Cytomegalovirus Serostatus Pairing and Deceased Donor Kidney Transplant Outcomes in Adult Recipients With Antiviral Prophylaxis

摘要

Background. The objectives of this study are to investigate the impact of cytomegalovirus (CMV) donor (D)/recipient (R) serostatus on kidney transplant outcomes in recipients who received CMV prophylaxis and to investigate the association of individual antiviral agents (acyclovir, ganciclovir, and valganciclovir) with outcomes in high-risk recipients (D+/R-). Methods. By using the Organ Procurement and Transplant Network/United Network for Organ Sharing database, 25,058 deceased donor kidney recipients (>=18 years, 2004-2008) who received CMV prophylaxis were stratified into four groups: D+/R+ (11,875), D-/R+ (6046), D+/R- (4555), and D-/R- (2582). The impact of CMV D/R serostatus on acute rejection (6 months and 1 year posttransplant) and long-term outcomes of death-censored graft failure and mortality were compared. The impact of the individual antiviral agent on long-term outcome was further evaluated in the high-risk group (D+/R-). Results. In multivariate analysis, CMV D/R status was not associated with acute rejection. Compared with D -/ R-, D+/R- was associated with an increased risk for death-censored graft failure (hazard ratio= 1.28, P=0.01), all-cause mortality(hazard ratio = 1.36, P=0.003), and mortality because of viral infection (hazard ratio = 8.36, P=0.04). In the D + /R- group, valganciclovir usage was associated with a decreased risk for death-censored graft failure (hazard ratio = 0.65, P=0.007) and mortality because of viral infection (hazard ratio = 0.22, P=0.03) compared with ganciclovir usage. Conclusions. CMV mismatch (D+/R-) was no longer a risk factor for acute rejection in kidney recipients who received antiviral prophylaxis but was still an independent risk factor for death-censored graft failure, all-cause mortality, and viral infection-related mortality.